Disease · MONDO_0100233
Trials19
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.
1 to 19 of 19
Download this page as JSON| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05595369 | RECOVER-VITAL: Platform Protocol to Measure the Effects of Antiviral Therapies on Long COVID Symptoms | Phase 2 | 963 | 2025-12-02 | Long COVID, Long Covid19 | NIRMATRELVIR | Its record names the disease | ClinicalTrials.gov |
| NCT05576662 | Paxlovid for Treatment of Long Covid | Phase 2 | 168 | 2024-09-25 | Post-acute Sequelae of SARS-CoV-2 Infection, Long COVID | NIRMATRELVIR, RITONAVIR | Its record names the disease | ClinicalTrials.gov |
| NCT05472090 | A Phase 2 Study to Evaluate the Efficacy and Safety of TNX-102 SL in Patients With Multi-Site Pain Associated With Post-Acute Sequelae of SARS-CoV-2 Infection | Phase 2 | 63 | 2024-11-26 | Post-Acute Sequelae of SARS-CoV-2 (PASC) Infection, COVID-19, Long COVID, Long Haul COVID | CYCLOBENZAPRINE, CYCLOBENZAPRINE HYDROCHLORIDE | Its record names the disease | ClinicalTrials.gov |
| NCT05965726 | RECOVER-VITAL: Platform Protocol, Appendix to Measure the Effects of Paxlovid on Long COVID Symptoms | Phase 2 | 964 | Long COVID-19, Long COVID | NIRMATRELVIR, RITONAVIR | Its record names the disease | ClinicalTrials.gov | |
| NCT06404086 | RECOVER-SLEEP: Platform Protocol | Phase 2 | 830 | Long COVID, Long COVID-19, Hypersomnia, Sleep Disturbance | MELATONIN, MODAFINIL, SOLRIAMFETOL | Its record names the disease | ClinicalTrials.gov | |
| NCT06597682 | Evaluating Immunomodulatory Interventions in Post-Acute Sequelae of SARS-CoV-2 InfEction | Not applicable | 632 | Post-acute Sequelae of SARS-COV-2 Infection | BUDESONIDE, FORMOTEROL, MONTELUKAST, PREDNISONE, UBIDECARENONE | Its record names the disease | ClinicalTrials.gov | |
| NCT05513560 | RECLAIM: Recovering From COVID-19 Lingering Symptoms Adaptive Integrative Medicine | Phase 2/3 | 460 | Long COVID, Post COVID Condition, Post Acute Sequelae of COVID-19 | IBUDILAST, PENTOXIFYLLINE | Its record names the disease | ClinicalTrials.gov | |
| NCT06404099 | RECOVER-SLEEP: Platform Protocol, Appendix_A (Hypersomnia) | Phase 2 | 361 | Long COVID, Long COVID-19, Hypersomnia | MODAFINIL, SOLRIAMFETOL | Its record names the disease | ClinicalTrials.gov | |
| NCT06721949 | Taurine Supplementation in Long COVID | Phase 2/3 | 300 | Long COVID | TAURINE | Its record names the disease | ClinicalTrials.gov | |
| NCT06974084 | A Multi-Center, Individually-Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Superiority Trial to Evaluate the Efficacy of the Combination of Maraviroc and Atorvastatin for the Treatment of Subjects With Long COVID | Phase 2/3 | 252 | Long COVID | ATORVASTATIN, MARAVIROC | Its record names the disease | ClinicalTrials.gov | |
| NCT05874037 | Fluvoxamine for Long COVID-19 | Phase 2/3 | 191 | Long COVID | FLUVOXAMINE | Open Targets' reading of its record | ClinicalTrials.gov | |
| NCT05747534 | AT1001 for the Treatment of Long COVID | Phase 2 | 107 | Long COVID, Long COVID-19, Post Acute COVID-19 Syndrome, Post Acute Sequelae of COVID-19 | LARAZOTIDE | Its record names the disease | ClinicalTrials.gov | |
| NCT05668091 | A Decentralized, Randomized Phase 2 Efficacy and Safety Study of Nirmatrelvir/Ritonavir in Adults with Long COVID. | Phase 2 | 100 | Long COVID | NIRMATRELVIR, RITONAVIR | Open Targets' reading of its record | ClinicalTrials.gov | |
| NCT06316843 | Valacyclovir Plus Celecoxib for Post-Acute Sequelae of SARS-CoV-2 | Phase 2 | 59 | Long COVID, PASC Post Acute Sequelae of COVID 19 | CELECOXIB, VALACYCLOVIR | Its record names the disease | ClinicalTrials.gov | |
| NCT07089719 | Bevacizumab in Post-acute Sequelae of COVID-19 : Efficacy and Safety (Pilot Study) | Phase 2 | 21 | Dyspnea Caused by 2019-nCoV | BEVACIZUMAB | Its record names the disease | ClinicalTrials.gov | |
| NCT05638620 | Dual Sympathetic Blocks for Patients Experiencing Sympathetically-Mediated Symptoms From Long COVID | Phase 1 | 20 | Post Acute COVID-19 Syndrome, Long COVID, Long Covid19, COVID-19 Recurrent, Post-Acute COVID-19, Post-Acute COVID-19 Infection, SARS-CoV2 Infection, Post Acute Sequelae of COVID-19, Dysautonomia, Dysautonomia Like Disorder, Dysautonomia Orthostatic Hypotension Syndrome, Post COVID-19 Condition, Post-COVID Syndrome, Post COVID-19 Condition, Unspecified, Post-COVID-19 Syndrome | BUPIVACAINE | Its record names the disease | ClinicalTrials.gov | |
| NCT04997395 | Feasibility of Cannabidiol for the Treatment of Long COVID | Phase 2 | 12 | Long COVID | CANNABIDIOL | Open Targets' reading of its record | ClinicalTrials.gov | |
| NCT04905888 | Hyperbaric Oxygen for Long COVID-19 Pulmonary Sequela | Phase 2 | 0 | Covid19 | OXYGEN | Its record names the disease | ClinicalTrials.gov | |
| NCT05371288 | The Role of Glutathione Deficiency and MSIDS Variables in Long COVID-19 | Early phase 1 | 0 | COVID-19 | GLUTATHIONE, LIPOIC ACID, ALPHA | Its record names the disease | ClinicalTrials.gov |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0100233/trials